NightHawk flies in­to na­tion­al stock­pile deal with Cana­di­an gov­ern­ment for an­thrax drug

New name, new build­ing, new deal.

NightHawk Bio­sciences, which was known as Heat Bi­o­log­ics un­til last week, has fi­nal­ized a con­tract with the Cana­di­an gov­ern­ment to sup­ply its an­thrax treat­ment.

An­thim will be added to the coun­try’s na­tion­al stock­pile for $7.9 mil­lion CAD. The deal will help bol­ster the sup­ply of the in­hala­tion an­thrax treat­ment for the use against a po­ten­tial bio­threat.

NightHawk cit­ed the CDC’s re­port that says if a bioter­ror­ism at­tack were to hap­pen, the bac­te­ria that caus­es an­thrax (bacil­lus an­thracis) would be the most like­ly to be used, be­cause the spores can be eas­i­ly found in na­ture and pro­duced in a lab.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER